Clinical Trial Protocols
Kisspeptin Dosage in the Research Literature
Kisspeptin dosage data summarized here are drawn exclusively from published clinical research. All doses cited were administered to human participants in supervised research settings. Kisspeptin is not approved for any clinical indication; no doses here constitute therapeutic or personal recommendations.
KP-10 Half-Life
~4
Minutes (human plasma)
KP-54 Half-Life
~30
Minutes (human plasma)
IVF Trigger Dose
9.6
nmol/kg SC (Abbara 2015)
Live Birth Rate
62%
At optimal IVF dose
Intravenous bolus — kisspeptin-10 in men
George et al. (2011, JCEM) administered kisspeptin-10 as IV bolus doses of 0.3, 1.0, and 3.0 µg/kg to healthy men.[5] Dose-dependent LH elevation was documented within minutes. At 1.5 µg/kg/h continuous IV infusion, mean LH rose from 5.2 to 14.1 IU/L; LH pulse frequency increased from 0.7 to 1.0 pulses/hour; serum testosterone was elevated above baseline.
In men with type 2 diabetes and mild biochemical hypogonadism, a 0.3 µg/kg IV bolus of kisspeptin-10 raised LH approximately 2-fold and normalized testosterone over an 11-hour observation period (George 2013, Clinical Endocrinology).[6] No evidence of desensitization was observed during the study period.
How long does it take for kisspeptin to kick in?
LH rises were observed within minutes of IV bolus administration in the George 2011 and George 2013 study designs — consistent with the rapid pharmacokinetics of KP-10 (~4 min plasma half-life) and the direct upstream mechanism driving GnRH and LH release.[5][6] Subcutaneous administration has a slower absorption phase; onset timing from SC routes has not been as precisely characterized in the published literature.
Intravenous infusion — kisspeptin-54 in hypothalamic amenorrhea
Jayasena et al. (2014, JCEM) used continuous IV infusion of kisspeptin-54 at doses from 0.01 to 1.00 nmol/kg/h in women with hypothalamic amenorrhea.[7] LH pulse frequency increased approximately 3-fold; LH pulse secretory mass approximately 6-fold versus vehicle at effective doses. Higher doses (1.0 nmol/kg/h) showed desensitization over prolonged infusion.
Jayasena et al. (2009, JCEM) studied subcutaneous injection of kisspeptin-54 twice daily for 14 days in women with hypothalamic amenorrhea.[8] Acute response on day 1: LH rose approximately 24 IU/L. After 14 days of twice-daily injections, the LH response fell to approximately 2.5 IU/L — marked chronic tachyphylaxis.
Subcutaneous injection — IVF oocyte maturation trigger
The Abbara 2015 Phase 2 RCT (n=60) evaluated single SC doses of kisspeptin-54 at 3.2, 6.4, 9.6, and 12.8 nmol/kg in women undergoing IVF at high OHSS risk.[9] Oocyte maturation was triggered in 95% of participants at the 9.6 nmol/kg dose. Live birth rate at 9.6 nmol/kg: 62%. No moderate, severe, or critical OHSS was observed at any dose tested.
The prior proof-of-concept study (Jayasena 2014, JCI) used 9.6 nmol/kg SC kisspeptin-54 to demonstrate the first clinically successful IVF trigger producing viable embryos and clinical pregnancies.[10]
The second-dose protocol (Abbara 2017, Human Reproduction) used two doses of kisspeptin-54 in high-OHSS-risk patients (n=62) and improved oocyte maturation without increasing OHSS risk.[11]
Research context only. All doses and protocols on this page are drawn from published peer-reviewed studies. None constitute a recommendation for self-administration or clinical use. Kisspeptin has no approved clinical indication as of 2025.
Intranasal administration — 2025 clinical study
The first clinical demonstration of non-invasive intranasal kisspeptin-54 delivery was published in 2025 (eBioMedicine).[24] Kisspeptin-54 at 12.8 nmol/kg intranasally produced clinically significant LH elevations in healthy men, healthy women, and women with hypothalamic amenorrhea. No adverse events were reported. Kisspeptin-54 was stable for 60 days at 4 degrees C in the formulation studied. This study established proof-of-concept for a practical non-invasive delivery route.
Kisspeptin half-life
KP-10. Plasma half-life approximately 4 minutes in humans: 3.8 ± 0.3 min in men, 4.1 ± 0.4 min in women. Complete clearance approximately 30 minutes after IV bolus.[12]
KP-54. Plasma half-life approximately 27–32 minutes in humans; approximately 32 minutes in mouse pharmacokinetic studies.[12] The roughly 8-fold difference between KP-10 and KP-54 half-lives results from KP-54's larger molecular size (6142 Da versus 1302.5 Da) providing greater resistance to endopeptidase cleavage and protecting the C-terminal RF-amide motif from exopeptidase attack.
LH duration. At equal molar IV doses in mice, KP-54 sustained LH release for 1–4 hours versus 10–60 minutes for KP-10.[12]
What is the half-life of kisspeptin?
KP-10 half-life in humans: approximately 4 minutes. KP-54 half-life: approximately 27–32 minutes. The isoform determines the pharmacokinetic profile; these two values shaped the choice between IV bolus (KP-10, mechanistic studies) and continuous infusion or SC injection (KP-54, IVF trigger and HA restoration protocols).[12]
Why does kisspeptin-54 produce longer-lasting LH release than kisspeptin-10?
KP-54's larger molecular size provides greater resistance to endopeptidase cleavage compared to KP-10, resulting in slower plasma clearance and a more prolonged KISS1R activation window. The 8-fold half-life difference translates to approximately 4x–6x longer LH release duration at matched molar doses.[12]
Kisspeptin side effects observed in trials
A 2025 systematic review documented no serious adverse events across more than 1,000 kisspeptin administrations across multiple research centers using IV and SC routes (Velmurugan 2025, Current Medicinal Chemistry).[22]
A 2025 randomized crossover trial in 95 participants specifically assessed whether kisspeptin-54 provoked anxiety. State anxiety, cortisol, and blood pressure were unchanged versus placebo despite confirmed biological activity (elevated LH).[21]
The principal pharmacological concern documented in the literature is tachyphylaxis with chronic administration:
- Continuous high-dose IV infusion (1.0 nmol/kg/h) showed desensitization over prolonged administration in the Jayasena 2014 infusion study.[7]
- Twice-daily SC injections for 14 days caused marked tachyphylaxis: LH response fell from approximately 24 IU/L on day 1 to approximately 2.5 IU/L by day 14 (Jayasena 2009, JCEM).[8]
This KISS1R desensitization pattern is the primary pharmacological limiting factor for sustained therapeutic use of kisspeptin, not an acute safety concern. Short-duration pulsatile protocols have been explored to mitigate receptor downregulation.
What happens if you take too much kisspeptin?
Continuous high-dose infusion in research settings produced receptor desensitization and paradoxical suppression of LH output — the tachyphylaxis documented in the Jayasena 2014 and Jayasena 2009 studies.[7][8] Pulsatile and intermittent protocols were explored specifically to preserve receptor sensitivity. No serious adverse events were reported in the clinical literature from any dose studied.
Does repeated kisspeptin dosing cause receptor desensitization?
Yes, under chronic administration conditions. Twice-daily SC kisspeptin-54 for 14 days produced a 10-fold reduction in the LH response compared to the acute first dose.[8] Continuous IV infusion at 1.0 nmol/kg/h showed desensitization over the infusion period.[7] The mechanism is KISS1R downregulation and desensitization. KP-10's approximately 4-minute half-life theoretically allows KISS1R to reset between well-spaced administrations; pulsatile protocols exploiting this property were investigated in subsequent research.